Skip to main content
Premium Trial:

Request an Annual Quote

Modeling Software With New Launch and Eye on Funding, Teranode Takes Off

Premium

Listen closely enough to Neil Fanger, and you’ll find someone who really has taken the lessons of the bioinformatics bubble to heart. One of four cofounders of modeling informatics startup Teranode, Fanger eschews hyped-up catchphrases in favor of descriptions like “reasonable growth rate.”

That’s not to say Fanger lacks optimism. As Teranode prepared to launch version 2.5 of its Teranode Design Suite, he spoke with Genome Technology about the state of this almost-three-year-old company. Now at a staff of 25, Teranode began with Fanger, Joseph Duncan, Larry Arnstein, and Zang Lee — professionals who met through the University of Washington’s Cell Systems Initiative, most of whom had previous careers in software or related fields. Its technology is based on biological modeling and simulation software licensed from the university. The team has managed to complete a series A funding round, and are about to embark on their series B. Teranode now boasts 12 customers and recently signed an agreement with NIH to provide its software for the new chemical genomics initiative, Fanger says. “We’re pretty much growing as we see revenues ramping,” he adds.

Teranode’s suite is aimed at lab scientists looking to merge wet lab and in silico data, and can accommodate data from the public domain as well. The software designers looked at basic problems scientists confront: “manual spreadsheet development,” Fanger says, “accessibility of biological databases, … sharing and merging models.” Groups at MIT and Amgen are using biological and protein modeling software, he says, while pharmas are using the company’s chemical synthesis programs. Teranode is in the process of developing high-throughput screening and sample management solutions as well. Ultimately, Fanger says, the goal is to get institutes like these to run Teranode software essentially from start to finish, linking everything “into one major computing infrastructure.”

For those seeking algorithms Teranode hasn’t designed yet, the company offers a developer’s tool kit that customers can use to build software to suit their own needs, relying on a Teranode backbone.

In three years’ time, Fanger says he would like to see Teranode have 150 to 200 customers, and have successfully decreased R&D costs and time to market for new applications. While that’s quite a goal, he says market indicators suggest he’s not crazy: “We’re at the beginning of an emerging market. … We’re really starting to see companies put together budgets to make this happen.”

— Meredith Salisbury

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.